Cargando…
Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy
Image-guided tumor ablation eliminates tumor cells by physical or chemical stimulation, which shows less invasive and more precise in local tumor treatment. Tumor ablation provides a treatment option for medically inoperable patients. Currently, clinical ablation techniques are widely used in clinic...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483102/ https://www.ncbi.nlm.nih.gov/pubmed/36131929 http://dx.doi.org/10.3389/fimmu.2022.965120 |
_version_ | 1784791601194729472 |
---|---|
author | Yin, Li Li, Xing-yu Zhu, Lin-lin Chen, Gui-lai Xiang, Zhuo Wang, Qing-qing Bi, Jing-wang Wang, Qiang |
author_facet | Yin, Li Li, Xing-yu Zhu, Lin-lin Chen, Gui-lai Xiang, Zhuo Wang, Qing-qing Bi, Jing-wang Wang, Qiang |
author_sort | Yin, Li |
collection | PubMed |
description | Image-guided tumor ablation eliminates tumor cells by physical or chemical stimulation, which shows less invasive and more precise in local tumor treatment. Tumor ablation provides a treatment option for medically inoperable patients. Currently, clinical ablation techniques are widely used in clinical practice, including cryoablation, radiofrequency ablation (RFA), and microwave ablation (MWA). Previous clinical studies indicated that ablation treatment activated immune responses besides killing tumor cells directly, such as short-term anti-tumor response, immunosuppression reduction, specific and non-specific immune enhancement, and the reduction or disappearance of distant tumor foci. However, tumor ablation transiently induced immune response. The combination of ablation and immunotherapy is expected to achieve better therapeutic results in clinical application. In this paper, we provided a summary of the principle, clinical application status, and immune effects of tumor ablation technologies for tumor treatment. Moreover, we discussed the clinical application of different combination of ablation techniques with immunotherapy and proposed possible solutions for the challenges encountered by combined therapy. It is hoped to provide a new idea and reference for the clinical application of combinate treatment of tumor ablation and immunotherapy. |
format | Online Article Text |
id | pubmed-9483102 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94831022022-09-20 Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy Yin, Li Li, Xing-yu Zhu, Lin-lin Chen, Gui-lai Xiang, Zhuo Wang, Qing-qing Bi, Jing-wang Wang, Qiang Front Immunol Immunology Image-guided tumor ablation eliminates tumor cells by physical or chemical stimulation, which shows less invasive and more precise in local tumor treatment. Tumor ablation provides a treatment option for medically inoperable patients. Currently, clinical ablation techniques are widely used in clinical practice, including cryoablation, radiofrequency ablation (RFA), and microwave ablation (MWA). Previous clinical studies indicated that ablation treatment activated immune responses besides killing tumor cells directly, such as short-term anti-tumor response, immunosuppression reduction, specific and non-specific immune enhancement, and the reduction or disappearance of distant tumor foci. However, tumor ablation transiently induced immune response. The combination of ablation and immunotherapy is expected to achieve better therapeutic results in clinical application. In this paper, we provided a summary of the principle, clinical application status, and immune effects of tumor ablation technologies for tumor treatment. Moreover, we discussed the clinical application of different combination of ablation techniques with immunotherapy and proposed possible solutions for the challenges encountered by combined therapy. It is hoped to provide a new idea and reference for the clinical application of combinate treatment of tumor ablation and immunotherapy. Frontiers Media S.A. 2022-09-05 /pmc/articles/PMC9483102/ /pubmed/36131929 http://dx.doi.org/10.3389/fimmu.2022.965120 Text en Copyright © 2022 Yin, Li, Zhu, Chen, Xiang, Wang, Bi and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Yin, Li Li, Xing-yu Zhu, Lin-lin Chen, Gui-lai Xiang, Zhuo Wang, Qing-qing Bi, Jing-wang Wang, Qiang Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy |
title | Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy |
title_full | Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy |
title_fullStr | Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy |
title_full_unstemmed | Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy |
title_short | Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy |
title_sort | clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483102/ https://www.ncbi.nlm.nih.gov/pubmed/36131929 http://dx.doi.org/10.3389/fimmu.2022.965120 |
work_keys_str_mv | AT yinli clinicalapplicationstatusandprospectofthecombinedantitumorstrategyofablationandimmunotherapy AT lixingyu clinicalapplicationstatusandprospectofthecombinedantitumorstrategyofablationandimmunotherapy AT zhulinlin clinicalapplicationstatusandprospectofthecombinedantitumorstrategyofablationandimmunotherapy AT chenguilai clinicalapplicationstatusandprospectofthecombinedantitumorstrategyofablationandimmunotherapy AT xiangzhuo clinicalapplicationstatusandprospectofthecombinedantitumorstrategyofablationandimmunotherapy AT wangqingqing clinicalapplicationstatusandprospectofthecombinedantitumorstrategyofablationandimmunotherapy AT bijingwang clinicalapplicationstatusandprospectofthecombinedantitumorstrategyofablationandimmunotherapy AT wangqiang clinicalapplicationstatusandprospectofthecombinedantitumorstrategyofablationandimmunotherapy |